IL177328A0 - Controlled release formulations - Google Patents
Controlled release formulationsInfo
- Publication number
- IL177328A0 IL177328A0 IL177328A IL17732806A IL177328A0 IL 177328 A0 IL177328 A0 IL 177328A0 IL 177328 A IL177328 A IL 177328A IL 17732806 A IL17732806 A IL 17732806A IL 177328 A0 IL177328 A0 IL 177328A0
- Authority
- IL
- Israel
- Prior art keywords
- controlled release
- release formulations
- formulations
- controlled
- release
- Prior art date
Links
- 238000013270 controlled release Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/776,333 US20050175679A1 (en) | 2004-02-10 | 2004-02-10 | Controlled release formulations |
| PCT/US2005/004163 WO2005077346A1 (en) | 2004-02-10 | 2005-02-09 | Controlled release formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL177328A0 true IL177328A0 (en) | 2006-12-10 |
Family
ID=34827359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL177328A IL177328A0 (en) | 2004-02-10 | 2006-08-07 | Controlled release formulations |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20050175679A1 (https=) |
| EP (1) | EP1720532A1 (https=) |
| JP (1) | JP2007522223A (https=) |
| KR (1) | KR20060135769A (https=) |
| AU (1) | AU2005212355B2 (https=) |
| BR (1) | BRPI0506630A (https=) |
| CA (1) | CA2555882A1 (https=) |
| IL (1) | IL177328A0 (https=) |
| MX (1) | MXPA06009094A (https=) |
| WO (1) | WO2005077346A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007083984A1 (en) | 2006-01-23 | 2007-07-26 | Gwangju Institute Of Science And Technology | Conjugate comprising pharmaceutical active compound covalently bound to mucoadhesive polymer and transmucosal delivery method of pharmaceutical active compound using the same |
| KR100766820B1 (ko) | 2006-01-23 | 2007-10-17 | 광주과학기술원 | 단백질 또는 펩타이드의 경점막 운반 시스템 |
| US20080182819A1 (en) * | 2007-01-29 | 2008-07-31 | Act Iii Licensing, Llc | Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders |
| JP5258315B2 (ja) * | 2007-05-25 | 2013-08-07 | ロート製薬株式会社 | フルニソリド含有粘膜適用組成物 |
| US20130213393A1 (en) | 2009-12-22 | 2013-08-22 | Evoke Pharma, Inc. | Nasal formulations of metoclopramide |
| BR112014004418A8 (pt) * | 2011-08-25 | 2018-01-23 | Evoke Pharma Inc | método de tratamento de sintomas associados à gastroparesia feminina |
| EP3554489A4 (en) | 2016-12-15 | 2020-06-17 | Evoke Pharma, Inc. | TREATMENT FROM MODERATE TO HEAVY GASTROPARESIS |
| JP7217071B2 (ja) * | 2019-09-30 | 2023-02-02 | エルジー・ケム・リミテッド | 高吸水性樹脂およびその製造方法 |
| EP4230206A1 (en) * | 2020-10-15 | 2023-08-23 | Pharmbiotest Poland SP.ZO.O. | Pharmaceutical composition based on nalbuphine and/or its salts for nasal administration |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
| US5026825A (en) * | 1988-09-08 | 1991-06-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Intranasal calcitonin formulations |
| US5478565A (en) * | 1990-03-27 | 1995-12-26 | Warner-Lambert Company | Treatment of sinus headache |
| IT1250691B (it) * | 1991-07-22 | 1995-04-21 | Giancarlo Santus | Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac. |
| GB9202464D0 (en) * | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
| US5508282C1 (en) * | 1993-05-17 | 2001-01-23 | Tulin Silver Jeffrey | Composition and method for treating acute or chronic rhinosinusitis |
| US5897858A (en) * | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
| JP4137179B2 (ja) * | 1994-03-30 | 2008-08-20 | ジーエス ディベロップメント エービー | 生物付着性物質としての脂肪酸エステルの使用 |
| GB9416884D0 (en) * | 1994-08-20 | 1994-10-12 | Danbiosyst Uk | Drug delivery compositions |
| GB9605867D0 (en) * | 1996-03-20 | 1996-05-22 | Svedman Paul | Transdermal device |
| GB9700624D0 (en) * | 1997-01-14 | 1997-03-05 | Danbiosyst Uk | Drug delivery composition |
| US6433040B1 (en) * | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
| US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| US6261539B1 (en) * | 1998-12-10 | 2001-07-17 | Akwete Adjei | Medicinal aerosol formulation |
| AU2879100A (en) * | 1999-02-12 | 2000-08-29 | Miles A. Libbey Iii | Formulation and system for intra-oral delivery of pharmaceutical agents |
| US6225343B1 (en) * | 1999-06-16 | 2001-05-01 | Nastech Pharmaceutical Company, Inc. | Compositions and methods comprising morphine gluconate |
| HRP20010926A2 (en) * | 1999-06-16 | 2003-04-30 | Nastech Pharmaceutical Co | Pharmaceutical formulations and methods comprising intranasal morphine |
| GB9924797D0 (en) * | 1999-10-20 | 1999-12-22 | West Pharm Serv Drug Res Ltd | Compound |
| AU2001262992A1 (en) * | 2000-05-10 | 2002-02-18 | University Of Kentucky Research Foundation | System and method for intranasal administration of opioids |
| ITMI20010571A1 (it) * | 2001-03-19 | 2002-09-19 | Grisotech S A | Vaccini assorbibili per via trans-mucosale |
-
2004
- 2004-02-10 US US10/776,333 patent/US20050175679A1/en not_active Abandoned
-
2005
- 2005-02-09 EP EP05713244A patent/EP1720532A1/en not_active Withdrawn
- 2005-02-09 MX MXPA06009094A patent/MXPA06009094A/es active IP Right Grant
- 2005-02-09 AU AU2005212355A patent/AU2005212355B2/en not_active Ceased
- 2005-02-09 JP JP2006553213A patent/JP2007522223A/ja active Pending
- 2005-02-09 BR BRPI0506630-1A patent/BRPI0506630A/pt not_active Application Discontinuation
- 2005-02-09 CA CA002555882A patent/CA2555882A1/en not_active Abandoned
- 2005-02-09 WO PCT/US2005/004163 patent/WO2005077346A1/en not_active Ceased
- 2005-02-09 KR KR1020067016923A patent/KR20060135769A/ko not_active Ceased
-
2006
- 2006-08-07 IL IL177328A patent/IL177328A0/en unknown
-
2008
- 2008-03-17 US US12/049,893 patent/US20080221144A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005212355B2 (en) | 2010-06-17 |
| MXPA06009094A (es) | 2007-02-02 |
| KR20060135769A (ko) | 2006-12-29 |
| JP2007522223A (ja) | 2007-08-09 |
| CA2555882A1 (en) | 2005-08-25 |
| US20050175679A1 (en) | 2005-08-11 |
| EP1720532A1 (en) | 2006-11-15 |
| AU2005212355A1 (en) | 2005-08-25 |
| US20080221144A1 (en) | 2008-09-11 |
| BRPI0506630A (pt) | 2007-05-08 |
| WO2005077346A1 (en) | 2005-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0406819D0 (en) | Controlled release compositions | |
| ZA200802602B (en) | Controlled release formulation | |
| IL184460A0 (en) | Sustained release pharmaeutical formulations | |
| IL181265A0 (en) | Stabilizing formulations | |
| GB2424581B (en) | Formulations | |
| IL178596A0 (en) | Sustained release formulations | |
| IL185800A0 (en) | Controlled release formulations of octreotide | |
| EP2043647A4 (en) | FORMULATION WITH TAXED RELEASE AND CORRESPONDING METHODS | |
| EP1765385A4 (en) | IMPORTS COMPOSITION WITH DELAYED RELEASE | |
| ZA200707654B (en) | Formulations | |
| EP1909584A4 (en) | PRENYLFLAVONOID FORMULATIONS | |
| ZA200805646B (en) | Controlled release solid preparation | |
| ZA200805706B (en) | Controlled release solid preparation | |
| EP1951693A4 (en) | SOLID FORMULATIONS | |
| EP1753405A4 (en) | SLOW RELEASE PHARMACEUTICAL PREPARATION | |
| IL177328A0 (en) | Controlled release formulations | |
| IL179208A0 (en) | Intereferon formulations | |
| GB0311354D0 (en) | Controlled release formulations | |
| GB0417248D0 (en) | Formulations | |
| GB0417226D0 (en) | Formulations | |
| AP2006003706A0 (en) | Controlled release pharmaceutical compositions | |
| GB0322044D0 (en) | Controlled release compositions | |
| GB0427244D0 (en) | Novel formulations | |
| GB0427249D0 (en) | Novel formulations | |
| GB0426295D0 (en) | Novel formulations |